Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 9/20 | 0.43 |
| ▸ | PGR | P06401 | 6/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6066464 | 0.87 | LOXL2 (0.56) | DAOLOXL2NR3C1NR3C2PGR | |
| Hydrochloric Acid SCHEMBL27140516 | 0.85 | LOXL2 (0.55) | DAOLOXL2NR3C1NR3C2PGR | |
| Hydrochloric Acid SCHEMBL27144900 | 0.85 | LOXL2 (0.55) | DAOLOXL2NR3C1NR3C2PGR | |
| Trifluoroacetic Acid SCHEMBL23452218 | 0.79 | F2 (0.50) | NR3C1NR3C2PGRNAMPTCYP2C9 | |
| Trifluoroacetic Acid SCHEMBL29880434 | 0.79 | F2 (0.50) | NR3C1NR3C2PGRNAMPTCYP2C9 | |
| Trifluoroacetic Acid SCHEMBL23460742 | 0.77 | LOXL2 (0.40) | LOXL2NR3C1PGRHRH4HRH3 | |
| Trifluoroacetic Acid SCHEMBL19953228 | 0.75 | LOXL2 (0.82) | LOXL2 | |
| Trifluoroacetic Acid SCHEMBL23452474 | 0.75 | F2 (0.57) | NR3C1NR3C2PGRNAMPTCYP2C9 | |
| SCHEMBL23452339 | 0.74 | F2 (0.48) | DAONR3C1NR3C2PGRNAMPT | |
| SCHEMBL1388086 | 0.74 | DAO (0.46) | DAOLOXL2NR3C1NR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067665-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-06-27 | — | — | US | disclosed |
| US-6953857-B2 | Oxybenzamide derivatives useful for inhibiting factor Xa or viia | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-10-11 | — | — | US | disclosed |
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-07-28 | — | — | US | disclosed |
| EP-1349847-B1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| EP-1217000-A1 | Inhibitors of factor Xa and factor VIIa | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165058-A1 | Oxybenzamide derivatives useful for inhibiting factor Xa or Vlla | F12, F11, F5 | DAO 531/4885LOXL2 31/4885NR3C1 4856/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | DAO 648/4885LOXL2 191/4885NR3C1 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.